Tested samples

Cell lines and IC50 values (μM)

THP-1 HL60 Hep-G2 DU-145 MCF-7
3 74.76 ± 3.27 63.52 ± 5.2 90.99 ± 7.72 - 90.11 ± 7.26
5a 12.80 ± 1.34 23.52 ± 2.11 - - 77.37 ± 7.12
5d 25.19 ± 1.94 20.81 ± 1.97 43.75 ± 3.42 83.73 ± 6.43 56.54 ± 3.78
5e 27.03 ± 2.03 28.70 ± 2.37 33.22 ± 3.07 37.70 ± 2.71 28.98 ± 1.91
5f 10.42 ± 0.68 13.50 ± 1.14 19.94 ± 2.15 12.23 ± 1.19 17.28 ± 2.02
5g 4.76 ± 0.51 7.90 ± 0.64 10.12 ± 0.88 5.21 ± 0.28 10.32 ± 0.86
5h 27.78 ± 3.04 37.59 ± 3.16 53.28 ± 5.32 36.48 ± 3.09 45.12 ± 3.27
Doxorubicin 1.44 ± 0.09 2.17 ± 0.26 4.31 ± 0.36 2.59 ± 0.20 6.00 ± 0.72
(-): > 100 μM
Table 1: Cytotoxicity of the studied compounds towards cancer cell lines.